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Benjamín García-Espinosa1, Ernesto Moro-Rodríguez1,3* and Emilio Álvarez-Fernández2Abstract
Background: Human Papillomavirus (HPV) genotype distribution and co-infection occurrence was studied in
cervical specimens from the city of Madrid (Spain), as a contribution to the knowledge of Human Papillomavirus
genotype distribution and prevalence of carcinogenic HPV types in cervical lesions in Spain.
Methods: A total of 533 abnormal specimens, from the Hospital General Universitario “Gregorio Marañón” of
Madrid, were studied. These included 19 benign lesions, 349 cervical intraepithelial neoplasias 1 (CIN1), 158 CIN2-3
and 7 invasive cervical carcinomas (ICC). HPV genotyping was performed using PCR and tube array hybridization.
Results: We detected 20 different HPV types: 13 carcinogenic high-risk HPV types (HR-HPVs), 2 probably
carcinogenic high-risk HPV types (PHR-HPVs) and 5 carcinogenic low-risk HPV types (LR-HPVs). The most frequent
HPV genotypes found in all specimens were HPV16 (26.0%), 31 (10.7%) and 58 (8.0%). HPV 18 was only detected in
5.0%. Co-infections were found in 30.7% of CIN 1 and 18.4% cases of CIN2-3. The highest percentage of HR HPVs
was found in those specimens with a CIN2-3 lesion (93.7%).
Conclusion: As our study shows the current tetravalent vaccine could be effective in our geographical area for
preventing all the invasive cervical carcinomas. In addition, upon the estimates of the important presence of other
HR-HPV types – such as 31, 58, 33 and 52 – in different preneoplasic lesions the effectiveness of HPV vaccination in
our geographical area, and others with similar genotype distribution, should be limited.
Keywords: Human papillomavirus, Polymerase chain reaction, Genotyping, Squamous intraepithelial lesions,
Cervix, SpainBackground
Cervical cancer is the second most common cancer in
women worldwide. Several epidemiological studies make
it possible to conclude that persistent infection by certain
types of HPV is a causal and necessary factor for the de-
velopment of cervical cancer. A series of HPV-induced
precursor lesions, from LSIL to HSIL, may lead to ICC.
More than 40 anogenital HPV types exist [1]. From an
epidemiological point of view, based on their association* Correspondence: joseernesto.moro@urjc.es
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distribution, and reproduction in any mediumwith cervical cancer and precursor lesions, HPVs have
been classified in two groups: high risk of carcinogenesis
HPV types (HR-HPVs) and low risk of carcinogenesis
HPV types (LR-HPVs) [2,3]. There are also two additional
groups of probable high risk of carcinogenesis HPV types
(PHR-HPVs) and indeterminate risk of carcinogenesis
HPV (IR-HPVs) [4]. But even amongst the HR-HPV gen-
otypes, the variation of their oncogenic potential is
considerable, which may vary depending on specific
intratypic HPV variations or on ethnic background and
lifestyle factors of the human population under study.
HR-HPV 16 is the most common type in all studies,
but there are some differences regarding its prevalence
to other HPV types. HR-HPV 16 and 18 are estimatedCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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worldwide. Co-infection with multiple HPV types could
also increase the risk of cervical lesion. However, follow-
up studies suggest that the presence of multiple types
does not influence the course of HPV infections [5].
Two types of prophylactic vaccines have been devel-
oped to prevent cervical cancer: a bivalent vaccine
against HR-HPV 16 and 18, and a tetravalent vaccine
against HR-HPV 16/18 and LR-HPV 6 and 11 genotypes
that are responsible for most genital warts [6-8].
Some studies suggest that these vaccines seem to pro-
tect against some HPV 16-related types (31, 33, 35 and
52) and HPV 18-related types (39, 45, 59, 68 and 85).
However, vaccination against HPV 16/18 does not seem
to cross-protect against HPV 58 [9,10]. In addition, the
decreasing prevalence of the genotypes included in the
HPV vaccine may increase the prevalence of other coin-
fecting genotypes. This hypothesis suggests that the
elimination of certain genotypes by vaccination may
affect the distribution of other genotypes, and the im-
pact of the vaccine could vary [9].
Moreover, it has been demonstrated that the distribu-
tion of HPV 16 and 18 and the other HR-HPV genotypes
vary around the world both in type and relative inci-
dence. Therefore, the effect of HPV16/18 vaccines will,
at least to some degree, vary by region. However, re-
gional differences appear to become less pronounced
with increasing severity of lesions, as HPV 16 becomes
increasingly dominant [11].
The age-adjusted HPV prevalence in Spanish women
from general population is very low (3%) [12]. However,
this prevalence increase to 34.4% in Spanish women with
cytological alterations [13]. In addition, changes in sex-
ual behaviour and human migration flows could contrib-
ute to introduce some degree of variation both in
prevalence and distribution of HPV types [14]. Add-
itional genotypes that are not included in the first gener-
ation of human papillomavirus vaccines are frequently
associated with cervical cancer in Latin America and
Africa [15]. Over the past decade a large number of immi-
grants have arrived in Spain; more or less 40% come
from Latin America and 50% are women, and the preva-
lence of HR-HPVs is more than three times higher in
Latin Americans than in Spaniards [14]. Therefore, this
significant immigration from Latin America, as well as
from Eastern Europe and North Africa, possibly leads to
the appearance in Spain of additional carcinogenic geno-
types not included in current HPV vaccines [16,17].
For all these reasons, it is important to estimate the
prevalence of different HPV types found in cervical can-
cer in different geographic regions and over time in order
to study the carcinogenic function of each genotype, to
assess the impact of the current vaccines and to guide
the introduction of a new generation of them [13,18,19].The regional community of Madrid is located in the
centre of Spain and has a population of 6.4 million. In the
last ten years, a high influx of immigrants from Latin
America, Eastern Europe and North Africa has caused a
population increase of nearly 15 per cent. The objective
of this study is to provide epidemiological data regarding
the prevalence and distribution of different HPV geno-
types in samples with different grade of cervical lesions,
obtained in our geographical area, in order to understand
the carcinogenic potential of each of HPV type found
and to discern the impact of HPV vaccination on our
population.Methods
Specimen collection and diagnosis
This is a cross-sectional and retrospective study, in
which all cases diagnosed between January 2005 and July
2011 (1,137 abnormal specimens from fixed tissue sec-
tions of biopsies and LEEPs) were selected. Samples for
HPV testing, containing cervical carcinoma related
lesions, were collected by different departments of the
Hospital General Universitario “Gregorio Marañón” of
Madrid and submitted to the anatomical pathology la-
boratory of this hospital. In 533 of this specimens one or
several HPV types was detected. The population included
in this study had been selected for any type of gynaeco-
logic pathology. This hospital provides healthcare to a
population of about 750,000 individuals (11.5% of the
population of the regional community of Madrid).
The positive samples included 19 benign lesions
(genital warts, condylomas and papillomas), 349 cervical
intraepithelial neoplasias 1 (CIN1), 158 CIN2-3 and 7 in-
vasive cervical carcinomas (ICC).
Informed consent was not required for this study
since the results presented here come from HPV geno-
typing routinely performed, as an adjunct to the cyto-
logical and histological study, in an anatomical pathology
laboratory. The detection and genotyping was done in
clinical setting and in order to protect patient confidenti-
ality the identifiers of personal data were always deleted,
that is why it was not possible to determine the ethnic of
each patient. The study was supervised by the ethical
committee of our hospital (Comité ético de investigación
clínica - CEIC).Detection and genotyping of HPV
The DNA was obtained from fixed tissue sections of
buffered formalin and embedded in paraffin (Kit for
DNA extraction. Master Diagnostica SL Granada).
This DNA was used as a template to detect the pres-
ence of HPV DNA by PCR amplification using primers
specific GP5-6 L1 consensus region (HPV screening kit.
Master Diagnostica SL Granada).
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ose gel electrophoresis and ethidium bromide staining
on a UV transilluminator, considering the case as posi-
tive if it showed a band of 150 bp.
Among the HPV positive cases we identified the type
of virus using a kit that allows the detection of 14 specific
HPV types of high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68), 2 HPV types of intermediate-risk (53, 66)
of and 5 HPV types of low-risk (6, 11, 42, 43, 44). This
identification was performed by PCR amplification of a
fragment of 450 bp L1 consensus region and reverse
hybridization with probes specific for each type (HPV
GenoArray Test Kit. Ref: IHP301-C. Master Diagnostica
SL Granada. Supplier: HybriBio Limited, Hong Kong).
Two methods were used to estimate the frequency of
HPV positivity: percentages referred to the number of
lesions infected by one or several genotypes and percen-
tages referred to the total number of virus detected in
each kind of lesion and in the total of them.
Statistical analysis
Statistical analysis was performed using Stata version
11.1/SE (StataCorp. LP, TX, USA).
Relative frequencies of HPV genotypes were estimated
as percentages and their 95% confidence intervals were
obtained with Clopper-Pearson method based on exact
binomial distribution of tail areas.
Results
Distribution of viral genotypes
The percentage of HPV positivity in the total of speci-
mens studied was at less than 47% (533/1,137).
Taking into account overall data, we detected 20
different HPV types: 13 HR-HPVs, 2 PHR-HPVs and
5 LR-HPVs.
HPV 16 was the most common type (26.0%) followed,
in order of decreasing frequency, by HPV 31 (10.7%),
HPV 58 (8.0%), HPV 6 (6.2%), HPV 33 (6.1%), HPV 52
(5.7%), HPV 53 (5.1%), HPV 18 (5.0%), HPV 66 (4.4%)
and HPV 11 (4.3%).
HPV 16 was present in 35.3% of total lesions, HPV 31
in 14.4%, HPV 58 in 10.9%, HPV 6 in 8.4% and HPV 33
in 8.3% of them.Table 1 Frequency of HPV positivity according to the type of




Benign lesions 19 (3.6%) 19 (10
CIN 1 349 (65.5%) 242 (69
CIN 2-3 158 (29.6%) 129 (81
ICC 7 (1.3%) 7 (10
Total cases 533 (100%) 397 (74In the whole of lesions included in our study, 63.0% of
HPVs detected were HR-HPVs, 12.2% were PHR-HPVs
and 15.2% were LR-HPVs. HPVs 16 and/or 18 were
founded in 41.3% of lesions and HPVs 6 and 11 in 14.1%
of them.
Nine (1.2%) of HPV-positive cases detected were clas-
sified as an uncharacterized type (HPV X), but it is likely
that this classification was related with a missed detec-
tion of known types and was not associated to an infec-
tion by HPV types to be discovered (Table 1).Relationship between diagnoses and HPV genotypes
In benign lesions, HPV 6 was the most common type
(42.1%) followed, in order of decreasing frequency, by
HPV 11 (26.3%), HPV 16 (15.8%), HPV 18 (5.3%) and
HPV 53 (5.3%).
21.1% of HPVs detected were HR-HPVs, 5.3% were
PHR-HPVs and 68.4% were LR-HPVs. HPVs 16 and/or
18 comprised 21.1% of HPV infections detected and HPVs
6 and/or 11 comprised 68.4% of them. Therefore, LR-HPV
types included in tetravalent vaccine were detected more
frequently than viruses not included in this vaccine.
In CIN1 cases, HPV 16 was the most common type
(18.2%) followed, in order of decreasing frequency, by
HPV 31 (12.0%), HPV 58 (9.0%), HPV 6 (6.4%), HPV 53
(6.4%), HPV 33 (6.0%), HPV 66 (6.0%), HPV 52 (5.2%),
HPV 18 (5.0%) and HPV 68 (4.8%).
HPV 16 was present in 26.1% of CIN1 lesions, HPV
31 in 17.2%, HPV 58 in 12.9%, HPV 53 in 9.2% and
HPV 6 in 9.2% of them.
HR-HPVs were detected in 51.0% of CIN1 lesions,
PHR-HPVs in 16.6% and LR-HPVs in 16.3% of them.
HPVs 16 and/or 18 were present in 32.4% of lesions and
HPVs 6 and/or 11 in 14.6% of them.
HR-HPV types not included in vaccines were de-
tected more frequently (59.9%) than carcinogenic viruses
included in vaccines (32.4%). LR-HPV types were infre-
quently identified as single infections (15.3%).
In CIN2-3 cases, HPV 16 was the most common type
(45.2%) followed, in order of decreasing frequency, by
HPV 31 (8.6%), HPV 52 (7.6%), HPV 33 (7.1%), HPV 58
(6.6%), HPV 18 (4.6%), HPV 6 (2.5%), HPV 11 (2.5%),







0%) 0 (0%) 1 (5.3%)
.3%) 107 (30.7%) 5 (1.4%)
.6%) 29 (18.4%) 3 (1.9%)
0%) 0 (0%) 0 (0%)
.5%) 136 (25.5%) 9 (1.7%)
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HPV 31 in 10.8%, HPV 52 in 9.5%, HPV 33 in 8.9%
and HPV 58 in 8.2% of them.
HR-HPVs were detected in 93.7% of CIN2-3 lesions,
PHR-HPVs in 3.8% and LR-HPVs in 6.3% of them. HPVs
16 and/or 18 were present in 61.4% of lesions and HPVs
6 and/or 11 in 6.3% of them.
HR-HPV types not included in vaccines were detected
with an inferior frequency (42.4%) to carcinogenic viruses
included in vaccines (61.4%). LR-HPV types were rarely
identified as single infections (4.7%).
In ICC cases, HPV 16 was the most common type
(71.4%) followed, in order of decreasing frequency, by
HPV 18 (14.3%) and HPV 11 (14.3%).
HR-HPVs were detected in 85.7% of ICC lesions and
LR-HPVs in 14.3% of them. PHR-HPVs were not detected
in this kind of lesions. HPVs 16 and/or 18 were present in




N % * CI95% % ** CI95% N % * CI
HR-HPVs
16 188 35.3 31.2-39.5 26.0 22.9-29.4 3 15.8 3.4
18 36 6.8 4.8-9.2 5.0 3.5-6.8 1 5.3 0.1
31 77 14.4 11.6-17.7 10.7 8.5-13.1 0 0 0.0
33 44 8.3 6.1-10.9 6.1 4.5-8.1 0 0 0.0
35 9 1.7 0.8-3.2 1.2 0.6-2.4 0 0 0.0
39 9 1.7 0.8-3.2 1.2 0.6-2.4 0 0 0.0
45 19 3.6 2.2-5.5 2.6 1.6-4.1 0 0 0.0
51 21 3.9 2.5-6.0 2.9 1.8-4.4 0 0 0.0
52 41 7.7 5.6-10.3 5.7 4.1-7.6 0 0 0.0
56 14 2.6 1.4-4.4 1.9 1.1-3.2 0 0 0.0
58 58 10.9 8.4-13.8 8.0 6.2-10.3 0 0 0.0
59 15 2.8 1.6-4.6 2.1 1.2-3.4 0 0 0.0
68 28 5.3 3.5-7.5 3.9 2.6-5.6 0 0 0.0
PHR-HPVs
53 37 6.9 4.9-9.4 5.1 3.6-7.0 1 5.3 0.1
66 32 6.0 4.1-8.4 4.4 3.1-6.2 0 0 0.0
LR-HPVs
6 45 8.4 6.2-11.1 6.2 4.6-8.3 8 42.1 20
11 31 5.8 4.0-8.2 4.3 2.9-6.0 5 26.3 9.1
42 3 0.6 0.1-1.6 0.4 0.1-1.2 0 0 0.0
43 1 0.2 0.0-1.0 0.1 0.0-0.8 0 0 0.0
44 5 0.9 0.3-2.2 0.7 0.2-1.6 0 0 0.0
X 9 1.7 0.8-3.2 1.2 0.6-2.4 1 5.3 0.1
N: total number of times which each genotype was detected.
* Percentages referred to the number of lesions infected by one or several genotyp
** Percentages referred to the total number of virus detected (722 viruses in the To
CI95%: 95% confidence intervals used for estimate percentages.The distribution of HPV types and the analysis be-
tween pathological groups vs. HPV risk types is shown
in Tables 2 and 3.
Genotypes found as co-infections
The percentages of multiple infections were 30.7% in
CIN1 cases and 18.4% in CIN2-3 cases. Multiple infec-
tions were not detected in benign lesions and in ICC.
In all sorts of lesions with multiple infections the most
common pattern of co-infection was double infection
with HPV 16 and 58 (6 cases), followed by double infec-
tion with HPV 16/31 (5 cases), HPV 16/53 (5 cases),
HPV 16/18 (4 cases) and 16/52 (4 cases).
In CIN1 multiple infections cases, most co-infections
consisted of two different genotypes (71.0%). 20.6% of
the cases showed triple genotype infection and only 6.5%
of them showed quadruple genotype infection. Surpris-
ingly, in one case (0.9%) five different genotypes wereording to the pathological diagnosis
nign lesions CIN 1
95% % ** CI95% N % * CI95% % ** CI95%
-39.6 15.8 3.4-39.6 91 26.1 21.5-31.0 18.2 14.9-21.9
-26.0 5.3 0.1-26.0 25 7.2 4.7-10.4 5.0 3.3-7.3
-0.0 0 0.0-0.0 60 17.2 13.4-21.6 12.0 9.3-15.2
-0.0 0 0.0-0.0 30 8.6 5.9-12.0 6.0 4.1-8.5
-0.0 0 0.0-0.0 6 1.7 0.6-3.7 1.2 0.4-2.6
-0.0 0 0.0-0.0 6 1.7 0.6-3.7 1.2 0.4-2.6
-0.0 0 0.0-0.0 16 4.6 2.6-7.3 3.2 1.8-5.2
-0.0 0 0.0-0.0 16 4.6 2.6-7.3 3.2 1.8-5.2
-0.0 0 0.0-0.0 26 7.4 4.9-10.7 5.2 3.4-7.5
-0.0 0 0.0-0.0 12 3.4 1.8-5.9 2.4 1.2-4.2
-0.0 0 0.0-0.0 45 12.9 9.6-16.9 9.0 6.7-11.9
-0.0 0 0.0-0.0 14 4.0 2.2-6.6 2.8 1.5-4.7
-0.0 0 0.0-0.0 24 6.9 4.5-10.1 4.8 3.1-7.1
-26.0 5.3 0.1-26.0 32 9.2 6.4-12.7 6.4 4.4-8.9
-0.0 0 0.0-0.0 30 8.6 5.9-12.0 6.0 4.1-8.5
.3-66.5 42.1 20.3-66.5 32 9.2 6.4-12.7 6.4 4.4-8.9
-51.2 26.3 9.1-51.2 20 5.7 3.5-8.7 4.0 2.5-6.1
-0.0 0 0.0-0.0 3 0.9 0.2-2.5 0.6 0.1-1.7
-0.0 0 0.0-0.0 1 0.3 0.0-1.6 0.2 0.0-1.1
-0.0 0 0.0-0.0 5 1.4 0.5-3.3 1.0 0.3-2.3
-26.0 5.3 0.1-26.0 5 1.4 0.5-3.3 1.0 0.3-2.3
es (533 Total lesions, 19 benign lesions and 349 CIN 1).
tal of lesions, 19 in the Benign lesions and 499 in CIN 1).
Table 3 Distribution of HPV genotypes found in the study according to the pathological diagnosis
Genotype
found
CIN 2-3 Invasive carcinoma
N % * CI95% % ** CI95% N % * CI95% % ** CI95%
HR-HPVs
16 89 56.3 48.2-64.2 45.2 38.1-52.4 5 71.4 29.0-96.3 71.4 29.0-96.3
18 9 5.7 2.6-10.5 4.6 2.1-8.5 1 14.3 0.4-57.9 14.3 0.4-57.9
31 17 10.8 6.4-16.7 8.6 5.1-13.5 0 0 0.0-0.0 0 0.0-0.0
33 14 8.9 4.9-14.4 7.1 3.9-11.6 0 0 0.0-0.0 0 0.0-0.0
35 3 1.9 0.4-5.4 1.5 0.3-4.4 0 0 0.0-0.0 0 0.0-0.0
39 3 1.9 0.4-5.4 1.5 0.3-4.4 0 0 0.0-0.0 0 0.0-0.0
45 3 1.9 0.4-5.4 1.5 0.3-4.4 0 0 0.0-0.0 0 0.0-0.0
51 5 3.2 1.0-7.2 2.5 0.8-5.8 0 0 0.0-0.0 0 0.0-0.0
52 15 9.5 5.4-15.2 7.6 4.3-12.2 0 0 0.0-0.0 0 0.0-0.0
56 2 1.3 0.2-4.5 1.0 0.1-3.6 0 0 0.0-0.0 0 0.0-0.0
58 13 8.2 4.5-13.7 6.6 3.6-11.0 0 0 0.0-0.0 0 0.0-0.0
59 1 0.6 0.0-3.5 0.5 0.0-2.8 0 0 0.0-0.0 0 0.0-0.0
68 4 2.5 0.7-6.4 2.0 0.6-5.1 0 0 0.0-0.0 0 0.0-0.0
PHR-HPVs
53 4 2.5 0.7-6.4 2.0 0.6-5.1 0 0 0.0-0.0 0 0.0-0.0
66 2 1.3 0.2-4.5 1.0 0.1-3.6 0 0 0.0-0.0 0 0.0-0.0
LR-HPVs
6 5 3.2 1.0-7.2 2.5 0.8-5.8 0 0 0.0-0.0 0 0.0-0.0
11 5 3.2 1.0-7.2 2.5 0.8-5.8 1 14.3 0.4-57.9 14.3 0.4-57.9
42 0 0 0.0-0.0 0 0.0-0.0 0 0 0.0-0.0 0 0.0-0.0
43 0 0 0.0-0.0 0 0.0-0.0 0 0 0.0-0.0 0 0.0-0.0
44 0 0 0.0-0.0 0 0.0-0.0 0 0 0.0-0.0 0 0.0-0.0
X 3 1.9 0.4-5.4 1.5 0.3-4.4 0 0 0.0-0.0 0 0.0-0.0
N: total number of times which each genotype was detected.
* Percentages referred to the number of lesions infected by one or several genotypes (158 CIN 2-3 and 7 invasive carcinomas).
** Percentages referred to the total number of virus detected (197 viruses in CIN 2-3 and 7 in Invasive carcinomas).
CI95%: 95% confidence intervals used for estimate percentages.
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were found.
The most common pattern of co-infection was double
infection with HPV 16 and 58 (5 cases). Other patterns
of co-infection were: HPV 16/31 (4 cases), HPV 16/53
(4 cases), HPV 16/18 (3 cases), and HPV 31/6 (3 cases).
In this kind of multiple infections, HPV 16 was the
most common type (16.3%) followed, in order of de-
creasing frequency, by HPV 31 (10.5%), HPV 66 (9.7%),
HPV 58 (7.4%), HPV 68 (7.4%), HPV 53 (7.4%), HPV 33
(6.2%), HPV 52 (6.2%), HPV 18 (4.7%) and HPV 6 (4.7%).
HR-HPVs were detected in 96.3% of CIN1 lesions with
co-infection, PHR-HPVs in 37.4% and LR-HPVs in 15.9%
of them. HPVs 16 and/or 18 were present in 46.7% of
this cases and HPVs 6 and/or 11 in 15.0% of them.
In CIN2-3 multiple infections cases, most co-infections
consisted of two different genotypes (69.0%). 27.6% ofcases showed triple genotype infection and only 3.4% of
them showed quadruple genotype infection.
The most common pattern of co-infection was double
infection with HPV 16 and 52 (3 cases) and triple infec-
tion with HPV 16, 33 and 58 (2 cases).
In this kind of multiple infections, HPV 16 was the
most common type (23.5%) followed, in order of decreas-
ing frequency, by HPV 33 (11.8%), HPV 52 (11.8%), HPV
58 (8.8%), HPV 31 (7.4%), HPV 68 (5.9%), HPV 18
(4.4%), HPV 45 (4.4%), HPV 53 (4.4%) and HPV 6 (4.4%).
HR-HPVs were detected in 100% of CIN2-3 lesions
with co-infection, PHR-HPVs in 17.2% and LR-HPVs in
13.8% of them. HPVs 16 and/or 18 were present in
62.1% of this cases and HPVs 6 and/or 11 in 13.8% of
them.
The data concerning co-infections are shown in
Tables 4 and 5.
Table 4 Pathological diagnoses and co-infection occurrence
Pathological
diagnosis
2 HPV types 3 HPV types 4 HPV types 5 HPV types 6 HPV types Total
nº (%) nº (%) nº (%) nº (%) nº (%) nº (%)
CIN 1 76 (71.0%) 22 (20.6%) 7 (6.5%) 1 (0.9%) 1 (0.9%) 107 (78.7%)
CIN 2-3 20 (69.0%) 8 (27.6%) 1 (3.4%) 0 (0.0%) 0 (0.0%) 29 (21.3%)
Total 96 (70.6%) 30 (22.1%) 8 (5.9%) 1 (0.7%) 1 (0.7%) 136 (100%)
Percentage referred to total of co-infections (n = 136).
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Of all the lesions, HPV 16 was the most frequent geno-
type. This finding is in accordance with many other
studies carried out worldwide [20]. In our study, this
genotype was present in 35.3% of total lesions. However,
in a previous study carried in our hospital from 1993 to
2000, the HPV 16 presence in the total number of lesions
was somewhat higher than at present (39%) [21]. Also, in




N % * CI95% % ** CI95
HR-HPVs
16 42 39.3 30.0-49.2 16.3 12.0-
18 12 11.2 5.9-18.8 4.7 2.4-8
31 27 25.2 17.3-34.6 10.5 7.0-1
33 16 15.0 8.8-23.1 6.2 3.6-9
35 1 0.9 0.0-5.1 0.4 0.0-2
39 3 2.8 0.6-8.0 1.2 0.2-3
45 11 10.3 5.2-17.7 4.3 2.2-7
51 11 10.3 5.2-17.7 4.3 2.2-7
52 16 15.0 8.8-23.1 6.2 3.6-9
56 6 5.6 2.1-11.8 2.3 0.9-5
58 19 17.8 11.0-26.3 7.4 4.5-1
59 6 5.6 2.1-11.8 2.3 0.9-5
68 19 17.8 11.0-26.3 7.4 4.5-1
PHR-HPVs
53 19 17.8 11.0-26.3 7.4 4.5-1
66 25 23.4 15.7-32.5 9.7 6.4-1
LR-HPVs
6 12 11.2 5.9-18.8 4.7 2.4-8
11 5 4.7 1.5-10.6 1.9 0.6-4
42 3 2.8 0.6-8.0 1.2 0.2-3
43 1 0.9 0.0-5.1 0.4 0.0-2
44 3 2.8 0.6-8.0 1.2 0.2-3
X 0 0 0.0-0.0 0 0.0-0
N: total number of times which each genotype was detected.
* Percentages referred to the number of lesions infected by one or several genotyp
**Percentages referred to the total number of virus detected in each kind of lesion
CI95%: 95% confidence intervals used for estimate percentages.2006 to 2007, this presence was even lower than ours
(21.2%) [17].
As expected, HPV16 presence increased in accordance
with the grade of the lesion (15.8% in benign lesions,
26.1% in CIN1 cases, 56.3% in CIN2-3 cases and 71.4%
in ICC).
HPV 31 was the second most frequent genotype in
CIN1 lesions and in CIN2-3 lesions. In a study carried
in an eastern region of Spain, HPV 31 was also theCIN 2-3
% N % * CI95% % ** CI95%
21.4 16 55.2 35.7-73.6 23.5 14.1-35.4
.0 3 10.3 2.2-27.4 4.4 0.9-12.4
4.9 5 17.2 5.8-35.8 7.4 2.4-16.3
.9 8 27.6 12.7-47.2 11.8 5.2-21.9
.1 2 6.9 0.8-22.8 2.9 0.4-10.2
.4 1 3.4 0.1-17.8 1.5 0.0-7.9
.5 3 10.3 2.2-27.4 4.4 0.9-12.4
.5 1 3.4 0.1-17.8 1.5 0.0-7.9
.9 8 27.6 12.7-47.2 11.8 5.2-21.9
.0 1 3.4 0.1-17.8 1.5 0.0-7.9
1.3 6 20.7 8.0-39.7 8.8 3.3-18.2
.0 1 3.4 0.1-17.8 1.5 0.0-7.9
1.3 4 13.8 3.9-31.7 5.9 1.6-14.4
1.3 3 10.3 2.2-27.4 4.4 0.9-12.4
4.0 2 6.9 0.8-22.8 2.9 0.4-10.2
.0 3 10.3 2.2-27.4 4.4 0.9-12.4
.5 1 3.4 0.1-17.8 1.5 0.0-7.9
.4 0 0 0.0-0.0 0 0.0-0.0
.1 0 0 0.0-0.0 0 0.0-0.0
.4 0 0 0.0-0.0 0 0.0-0.0
.0 0 0 0.0-0.0 0 0.0-0.0
es (107 CIN 1 and 29 CIN 2-3 lesions).
(257 virus in CIN 1 and 68 in CIN 2-3 lesions).
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presence found in these (10.8%) was very similar to the
presence obtained in our study (10.8%) [19]. Previous
meta-analysis reported the second position of HPV 31 in
LSILs in Europe [11,20], and our results confirm this
finding.
After HPV 16 and 31, HPV 58 was the third most
common genotype found in our study. This event should
be explained by the large number of immigrants who
arrived in Spain over the past decade from Latin America,
where this genotype is the second most frequently
detected in HSIL after HPV 16 [13,19]. However, add-
itional studies are needed to confirm this hypothesis.
Moreover, the HPV 58 presence was somewhat higher
in CIN1 cases (12.9%) than in CIN2-3 cases (8.2%), but
this finding doesn’t have statistical significance attending
the 95% confidence intervals used for estimate these
percentages (9.6-16.9 versus 4.5-13.7).
Our HPV 58 findings are in accordance with other
recent study carried in a south-eastern region of Spain
in which HPV 58 was the third most common genotype
found and its frequency progressively decreased as
lesions showed higher grades of dysplasia [22]. As some
authors have reported, this decreasing HPV 58 frequency
with the severity of the lesion may indicate that, despite
the high frequency of HPV58 found in our area, LSIL
caused by HPV58 would have less likelihood to progress
to HSIL than a LSIL caused by HPV16 [22].
Globally, HPV 6 was the fourth most common geno-
type found in our study. Also, HPV 6 and 11 were the
most frequent genotype in benign lesions (respectively,
42.1% and 26.3%); but, surprisingly, HPV 16 was present
in third position (15.8%), as a single infection, in this
type of lesions.
Some authors have reported that LR-HPV types -such
as HPV 6 or HPV 11- are rarely identified as single infec-
tions in invasive cervical cancer [18]. In the previous
study carried in our hospital, from 1993 to 2000, one case
of single LR-HPV type infection in cervical cancer was
reported [21]. Our current findings confirm that the
detection of a single LR-HPV type (HPV 11) in ICC
is a possible event. Further efforts are needed to under-
stand in which conditions these HPV types can indeed
induce invasive cervical cancer in rare circumstances.
In our study, the HPV 33 and 52 were the fifth and
sixth most common types obtained. HPV 33 presence
was basically no difference in CIN1 cases (8.6%) than in
CIN2-3 cases (8.9%). This finding is in disagreement
with the previously mentioned study carried in a south-
eastern region of Spain in which HPV 33 frequency
increased in parallel with the severity of the lesion [22].
One previous meta-analysis reported the seventh
position of HPV 52 in HSIL in Europe [20], although in
our study HPV 52 was third in these types of lesions.Therefore, the carcinogenic importance of this genotype
is possibly increasing in our region at present.
Regarding the frequency of cases with the HPV 18
genotype is significant in our study that the frequency is
not as high as the published in other international series.
This data is in accordance with other published studies
in Spain, in which HPV type 18 does not appear as a
common type in the general population in our country
[17]. Also, apparently, the HPV 18 presence was higher
in CIN1 cases (7.2%) than in CIN2-3 cases (5.7%), but
this finding doesn’t have statistical significance attending
the 95% confidence intervals used for estimate these per-
centages (4.7-10.4 versus 2.6-10.5).
As expected, HPV 16 and 18 presence was appreciably
lower in CIN1 cases (32.4%) than in CIN2-3 cases
(61.4%). However, in a study carried in a north-eastern
region of Spain from 1999 to 2005, the joint frequency
of these genotypes was considerably higher (55% in
CIN 1 cases, versus 80% in CIN 2 cases and 90% in
CIN 3 cases) [16].
Moreover, in the earliest study carried in our hospital,
from 1993 to 2000, the HPV 16/18 frequency was some-
what higher than in our current study (43% in LSIL and
67% en HSIL) [21]. However, in a later study also carried
in our hospital, the frequency of 16/18 HPV types was
similar to our present study (41% in all types of lesions)
[23]. Therefore, the joint frequency of these genotypes
and its carcinogenic importance is possibly decreasing
over time in our region.
A relationship was found between lesions and HR-
HPVs frequency. Thus, these genotypes were found more
frequently in CIN2-3 cases (93.7%) than in CIN1 cases
(51.0%) or benign lesions (21.1%). The HR-HPVs pres-
ence found in our study in CIN2-3 cases (93.7%) was
similar to the frequency found in the previous studies
carried in a region of northern Spain (88.1%) and in a
region in eastern Spain (87.4%) [13,19].
Another issue worth mentioning is the co-infection
occurrence, which seems to be more frequent in CIN1
cases (30.7%) than in CIN2-3 cases (18.4%). This finding
is in accordance with the study carried in a south-eastern
Spanish region mentioned above [22]; but it is at vari-
ance with the other previously mentioned study carried
in a region in eastern Spain, in which the percentages of
multiple infections were lower than in our study, and
there were no considerable differences between groups
of lesions (4.8% in LSIL and 3.7% in HSIL) [19].
In all types of lesions with multiple infections, the most
common pattern of co-infection was double infection
with HPV 16 and 58 (6 cases). The same result was found
in the previously mentioned study carried in a region in
northern Spain [13]. However, the most common pattern
of co-infection in HSILs cases was double infection with
HPV 16 y 52. It is unknown whether the association of
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crease carcinogenic risk. Further efforts are needed to
clarify this hypothesis.
Conclusion
Regional variations in prevalence and distribution of HPV
types have been verified in several epidemiological studies.
In some countries such as Spain, these changes could be
due to the arrival of a large number of women immigrants
over the past decade. Furthermore, the generalized intro-
duction of a HPV vaccination could produce an epidemio-
logical pattern change and, consequently, in the coming
years the majority of HPV infections could be produced
by HPV types different from 16 and 18.
As our study shows the current tetravalent vaccine
could be effective in our geographical area for preventing
all the invasive cervical carcinomas, however, the joint
frequency of HPV 16/18 and its carcinogenic import-
ance is possibly decreasing over time in our region. In
addition, our study provides estimates of the important
presence of other HR-HPV types – such as 31, 58, 33
and 52 – in different preneoplasic lesions. Thus, in the
future the effectiveness of HPV vaccination in our geo-
graphical area and others with similar genotype distri-
bution should be limited.
Therefore, the assessment of the distribution of HPV
types associated with cervical cancer, in different geo-
graphic areas and over time, is necessary in order to
apply the correct diagnostic and therapeutic measures in
each region, to assess the impact of current vaccines and
to guide the introduction of a new generation of them.Weaknesses of the study
Our study presents some limitations. First, the origin of
the samples from only one hospital may do hard to
generalize the results to the entire population of Spain.
However, this hospital is a reference centre in which
patients of many districts and municipalities of the
Region of Madrid are attended. Also, the results obtained
in this study agree with data about population located in
other Spanish regions and previously published.
Second, whereas more than 40 anogenital HPV types
exist, only 20 were detected in this study. But all the
HPVs genotypes usually implicated in the origin of the
cervical cancer are detected.
Third, the small sample size of benign lesions and ICC
affect to the study’s significance. However, the difficulty
to obtain ICC cases in Spain gives value to these results.
In the future, it would be of interest to obtain more
cases for further studies.
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